Press Room http://www.news.sanofi.us/ MediaRoom Surveys Find Adults with Type 2 Diabetes Are More Willing to Take Action to Achieve A1C Targets Quicker than Physicians and Other Medical Professionals Perceive http://www.news.sanofi.us/2016-07-20-Surveys-Find-Adults-with-Type-2-Diabetes-Are-More-Willing-to-Take-Action-to-Achieve-A1C-Targets-Quicker-than-Physicians-and-Other-Medical-Professionals-Perceive -- Findings reveal that some patients are frustrated and discontinued medication because they were not reaching their individualized A1C target quick enough -- Wed, 20 Jul 2016 09:05:00 -0400 http://www.news.sanofi.us/2016-07-20-Surveys-Find-Adults-with-Type-2-Diabetes-Are-More-Willing-to-Take-Action-to-Achieve-A1C-Targets-Quicker-than-Physicians-and-Other-Medical-Professionals-Perceive Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease http://www.news.sanofi.us/2016-07-12-Award-Winning-Chef-Elizabeth-Falkner-Reveals-Her-Struggle-with-Atopic-Dermatitis-to-Highlight-the-Physical-and-Psychological-Impact-of-the-Disease Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis. Tue, 12 Jul 2016 07:00:00 -0400 http://www.news.sanofi.us/2016-07-12-Award-Winning-Chef-Elizabeth-Falkner-Reveals-Her-Struggle-with-Atopic-Dermatitis-to-Highlight-the-Physical-and-Psychological-Impact-of-the-Disease Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide http://www.news.sanofi.us/2016-06-12-Sanofi-Announces-Positive-Phase-3-Results-for-Investigational-Titratable-Fixed-Ratio-Combination-of-Insulin-Glargine-and-Lixisenatide - Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide - Sun, 12 Jun 2016 15:54:00 -0400 http://www.news.sanofi.us/2016-06-12-Sanofi-Announces-Positive-Phase-3-Results-for-Investigational-Titratable-Fixed-Ratio-Combination-of-Insulin-Glargine-and-Lixisenatide Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting http://www.news.sanofi.us/2016-06-11-Successful-Switch-to-Sanofis-Toujeo-Evaluated-in-a-Real-World-Setting Sat, 11 Jun 2016 11:01:00 -0400 http://www.news.sanofi.us/2016-06-11-Successful-Switch-to-Sanofis-Toujeo-Evaluated-in-a-Real-World-Setting Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-that-Dupilumab-Used-with-Topical-Corticosteroids-TCS-was-Superior-to-Treatment-with-TCS-Alone-in-Long-term-Phase-3-Trial-in-Inadequately-Controlled-Moderate-to-Severe-Atopic-Dermatitis-Patients - These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 - Mon, 06 Jun 2016 09:14:00 -0400 http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-that-Dupilumab-Used-with-Topical-Corticosteroids-TCS-was-Superior-to-Treatment-with-TCS-Alone-in-Long-term-Phase-3-Trial-in-Inadequately-Controlled-Moderate-to-Severe-Atopic-Dermatitis-Patients